CTOs on the Move

OpenTrons

www.opentrons.com

 
We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other`s results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century`s most important questions.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.opentrons.com
  • 45-18 Court Square West
    Long Island City, NY USA 11101
  • Phone: 857.577.7656

Executives

Name Title Contact Details

Funding

OpenTrons raised $10M on 03/27/2018

Similar Companies

Ash Stevens Inc

Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to

Hecker and Associates

Hecker and Associates is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioDuro

BioDuro, now a PPD company, is a leading integrated drug discovery outsourcing company that provides high-quality, integrated research and development services to meet the growing needs of the global biotechnology and pharmaceutical industries. Together, PPD and BioDuro have the expertise to perform a broad range of research and development services for pharmaceutical and biotech clients from discovery through Phase IV. Founded in 2005, BioDuro has more than 675 employees, the majority of whom are based in Beijing, where the company operates a state-of-the-art, 110,000-square-foot laboratory. BioDuro provides high-quality medicinal chemistry, discovery biology, pharmacology, synthesis, bioanalytical and drug safety evaluation services. Its discovery biology services range from reagent generation to assay development to screening and biochemistry.

Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Targacept

Targacept`s clinical pipeline is built on a unique class of therapeutic targets.